Bio/Pharma Business

The principal objective of the annual PharmSource–Pharmaceutical Technology outsourcing survey is to gauge overall business trends in the contract manufacturing and research businesses. This year's edition documents an industry that is in good health but facing a new set of dynamics.

Pharmaceutical Technology provides perspective on pharmaceutical manufacturing activity, assessing the product portfolios, prescription volumes, revenues, and capital spending plans of more than 500 drug-makers. Novartis leads in diversity, with 889 products; Pfizer leads in number of scrips (352 million) and revenue ($44 billion). And generics companies are coming up on the inside.

The laboratory supplier landscape is undergoing a radical makeover.

Cambrex Reports Loss; Advances Biosciences Business

The big question for pharmaceutical services providers coming into 2006 is: will the good times continue to roll?

From politics to paychecks and downsizings to deadlines-what it's like to work for one of the world's largest industries.

Pfizer to Shut Parsippany Plant

Contract services providers gained a valuable look into major market conditions, offshoring trends, and 2006 growth opportunities during a morning presentation entitled "CMC Sourcing in transition: Consolidation, Offshoring, and the Market Outlook," presented by Jim Miller. Miller is president of PharmSource (Springfield, VA, www.pharmsource.com), publisher of the Bio/Pharmaceutical Outsourcing , and contributing editor of Pharmaceutical Technology.

Roche Puts Hold on Tamiflu in US

Novartis Purchases Chiron in a Total Buyout

Biogen to Cut Jobs

MGI Pharma To Buy Guilford

Teva Absorbs Ivax In $7.4 Billion Bid

Aptuit To Purchase Quintiles

Able Labs Files for Chapter 11

Xanodyne Acquires aaiPharma Assets

Able Interim Chief Resigns Amid Drug Recall

Singapore is competing aggressively with India and China for a piece of the Asian sourcing business.

Schering AG To Cut Plants and Staff

Wyeth and Purdue Announce Restructuring Plans

Eli Lilly Scales Back Planned Virginia Insulin Plant

A myopic focus on short-term growth can endanger the community. The question is, can we enlighten our self-interest before the edifice falls down around our ears?

The Chapter 11 bankruptcy filing of aaiPharma (Wilmington, NC, www.aaipharma.com), parent of AAI Development Services, was the culmination of an agonizing year-long odyssey. It also was a first step in restoring one of the best-known brands in the CRO industry.

New Graduate Program Focuses On Pharmaceutical Technology

Pharmaceutical Technology has joined with INTERPHEX to found GenerationNext, an award program to recognize emerging leaders in pharmaceutical science and technology.

Crucell and NIH Sign Ebola Vaccine Manufacturing Contract

Pfizer Announces $4B/Year Cutbacks

Managers of FDA-regulated firms must be proactive in how they manage their company?s compliance with good manufacturing practices regulations.

Achieving the promised benefits of offshore sourcing to India and China is more complicated than it seems.